CL2023003100A1 - Anticuerpo biespecífico anti–cldn4/anti–cd137 - Google Patents

Anticuerpo biespecífico anti–cldn4/anti–cd137

Info

Publication number
CL2023003100A1
CL2023003100A1 CL2023003100A CL2023003100A CL2023003100A1 CL 2023003100 A1 CL2023003100 A1 CL 2023003100A1 CL 2023003100 A CL2023003100 A CL 2023003100A CL 2023003100 A CL2023003100 A CL 2023003100A CL 2023003100 A1 CL2023003100 A1 CL 2023003100A1
Authority
CL
Chile
Prior art keywords
cldn4
antibody
bispecific
bispecific antibody
cancer
Prior art date
Application number
CL2023003100A
Other languages
English (en)
Inventor
Yoshiyuki Tenda
Masatoshi Yuri
Hiroki Sasaki
Fumiko Chiwaki
Masayuki Komatsu
Shigenori Yagi
Yoshiki Satake
Kazunori Hirayama
Hiroki Shirai
Original Assignee
Astellas Pharma Inc
Nat Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Nat Cancer Ct filed Critical Astellas Pharma Inc
Publication of CL2023003100A1 publication Critical patent/CL2023003100A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un objeto de la presente invención es proporcionar un anticuerpo biespecífico anti– CLDN4/anti–CD137 utilizable en el tratamiento del cáncer. Un anticuerpo biespecífico anti–CLDN4/anti–CD137 producido utilizando un anticuerpo anti–CLDN4 que se une a CLDN4 y un anticuerpo anti–CD137 que se une a CD137 tenía actividad agonística para CD137, promovía la producción de interferón γ por una célula T y mostraba actividad citotóxica contra una célula cancerosa que expresaba CLDN4 en una superficie celular de la misma. Además, se demostró que el anticuerpo biespecífico anti–CLDN4/anti–CD137 puede administrarse con seguridad a los monos. Por lo tanto, el anticuerpo biespecífico anti–CLDN4/anti–CD137 es utilizable en el tratamiento del cáncer humano.
CL2023003100A 2021-04-22 2023-10-18 Anticuerpo biespecífico anti–cldn4/anti–cd137 CL2023003100A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2021072429 2021-04-22

Publications (1)

Publication Number Publication Date
CL2023003100A1 true CL2023003100A1 (es) 2024-03-22

Family

ID=83722348

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003100A CL2023003100A1 (es) 2021-04-22 2023-10-18 Anticuerpo biespecífico anti–cldn4/anti–cd137

Country Status (16)

Country Link
EP (1) EP4327823A1 (es)
JP (2) JP7365654B2 (es)
KR (1) KR20230171465A (es)
CN (1) CN117222672A (es)
AR (1) AR125398A1 (es)
AU (1) AU2022262542A1 (es)
BR (1) BR112023021950A2 (es)
CA (1) CA3217637A1 (es)
CL (1) CL2023003100A1 (es)
CO (1) CO2023015630A2 (es)
CR (1) CR20230490A (es)
DO (1) DOP2023000230A (es)
EC (1) ECSP23087918A (es)
IL (1) IL307744A (es)
TW (1) TW202309083A (es)
WO (1) WO2022224997A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023219120A1 (ja) * 2022-05-12 2023-11-16 アステラス製薬株式会社 抗ｃｄ３７－抗ｃｄ３二重特異性抗体
WO2024085166A1 (ja) * 2022-10-19 2024-04-25 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
WO2008011756A1 (en) 2006-07-19 2008-01-31 Jen-Shyan Chen High power light emitting diode illuminating equipment with efficiently heat-dissipating module
DK2346994T3 (da) 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
JP2014193853A (ja) * 2013-03-01 2014-10-09 Japan Health Sciences Foundation 抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー
WO2019048040A1 (en) * 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
EP3735463A4 (en) * 2018-01-05 2022-03-02 Chugai Seiyaku Kabushiki Kaisha THERAPEUTIC AGENT INDUCING CYTOTOXICITY
JP2021518104A (ja) * 2018-03-14 2021-08-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法
CN112424229A (zh) * 2018-07-12 2021-02-26 F星贝塔有限公司 结合cd137和ox40的抗体分子

Also Published As

Publication number Publication date
JPWO2022224997A1 (es) 2022-10-27
JP2023182689A (ja) 2023-12-26
BR112023021950A2 (pt) 2023-12-19
KR20230171465A (ko) 2023-12-20
DOP2023000230A (es) 2023-12-15
WO2022224997A1 (ja) 2022-10-27
IL307744A (en) 2023-12-01
ECSP23087918A (es) 2023-12-29
CO2023015630A2 (es) 2023-11-30
TW202309083A (zh) 2023-03-01
CN117222672A (zh) 2023-12-12
JP7365654B2 (ja) 2023-10-20
AR125398A1 (es) 2023-07-12
CA3217637A1 (en) 2022-10-27
EP4327823A1 (en) 2024-02-28
CR20230490A (es) 2023-11-16
AU2022262542A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
CL2023003100A1 (es) Anticuerpo biespecífico anti–cldn4/anti–cd137
BR112021022812A2 (pt) Dosagem de inibidor de kras para tratamento de cânceres
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20210685A1 (es) Anticuerpos que se dirigen al gp120 de vih y metodos de uso
AR074220A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina y uso
EA201691748A1 (ru) Антитела анти-cd38 для лечения острого лимфобластного лейкоза
CO2021016552A2 (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
DOP2021000101A (es) Anticuerpos humanizados contra c-kit
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
CO2020006865A2 (es) Composiciones y métodos para el agotamiento de células cd5+
DOP2023000039A (es) Moléculas de unión a antígeno multi-específicas contra el vih y métodos de uso
AR112405A1 (es) Tratamiento de cáncer de mama triple negativo o cáncer colorrectal con metástasis hepáticas
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
AR099181A1 (es) Métodos para usar anticuerpos anti-steap1 e inmunoconjugados
PE20221039A1 (es) METODOS PARA USAR INMUNOCONJUGADOS ANTI-CD79b PARA TRATAR LINFOMA DIFUSO DE LINFOCITOS B GRANDES
MX2019003258A (es) Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana.
MX2021001870A (es) Metodo para tratar cancer pancreatico.
MX2020003947A (es) Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.
CO2022000064A2 (es) Dosificación modificada de tocilizumab subcutáneo para la artritis reumatoide
BR112022018203A2 (pt) Agentes bloqueadores de derramamento com estabilidade aumentada.
AR121633A1 (es) Anticuerpos anti-ccr8 para el tratamiento del cáncer
MX2022003357A (es) Combinación de anticuerpo anti-cd30 conjugado con un farmaco, anti-pd-1 y quimioterapia para el tratamiento de cánceres hematopoyéticos.
AR123631A1 (es) Anticuerpos anti-liv1 humanizados para el tratamiento del cáncer
CL2023000261A1 (es) Métodos de tratamiento de la neuralgia del trigémino